A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes.

Viberti, G; Kahn, SE; Greene, D; Herman, W; Zinman, B; Holman, R; Haffner, S; Levy, D; Lachin, J; Berry, R; Heise, M; Jones, N; Freed, M

Journal article

A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes.

Abstract:: OBJECTIVE: Therapies with metformin, sulfonylureas, or insulin improve glycemic control in the short term but do not prevent progressive islet beta-cell failure or long-term deterioration in glycemia. Our goal was to evaluate, in patients recently diagnosed with type 2 diabetes (<3 years), the long-term efficacy of monotherapy with rosiglitazone on glycemic control and on the progression of pathophysiological abnormalities associated with type 2 diabetes as compared with metformin or glyburide monotherapy. RESEARCH DESIGN AND METHODS: A Diabetes Outcome Progression Trial (ADOPT) is a randomized, double-blind, parallel-group study consisting of a screening visit, a 4-week placebo run-in, a 4-year treatment period, and an observational follow-up of approximately 3,600 drug-naïve patients with type 2 diabetes diagnosed within the previous 3 years. After run-in, patients will be randomized to rosiglitazone, glyburide, or metformin titrated to the maximum effective daily doses (8 mg rosiglitazone, 15 mg glyburide, or 2 g metformin). The primary outcome is time to monotherapy failure, defined as the time following titration to the maximal effective or tolerated dose when fasting plasma glucose exceeds 180 mg/dl (10 mmol/l). Secondary outcomes include measures of islet beta-cell function, insulin sensitivity, dyslipidemia, changes in urinary albumin excretion, plasminogen activator inhibitor-1 antigen, fibrinogen, and C-reactive protein. Safety and tolerability will also be evaluated. Patient-reported outcomes and resource utilization data will be collected and analyzed. CONCLUSIONS: ADOPT will provide data on the effect of mechanistically differing treatment options on metabolic control, beta-cell function, and markers of macrovascular disease risk in type 2 diabetes.

Publication status:: Published

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Viberti, G., Kahn, S. E., Greene, D., Herman, W., Zinman, B., Holman, R., Haffner, S., Levy, D., Lachin, J., Berry, R., Heise, M., Jones, N., & Freed, M. (2002). A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care, 25(10), 1737–1743.

MLA Style

Viberti, G., et al. “A Diabetes Outcome Progression Trial (ADOPT): an International Multicenter Study of the Comparative Efficacy of Rosiglitazone, Glyburide, and Metformin in Recently Diagnosed Type 2 Diabetes.” Diabetes Care, vol. 25, no. 10, 2002, pp. 1737–43.

Chicago Style

Viberti, G, SE Kahn, D Greene, W Herman, B Zinman, R Holman, S Haffner, et al. 2002. “A Diabetes Outcome Progression Trial (ADOPT): an International Multicenter Study of the Comparative Efficacy of Rosiglitazone, Glyburide, and Metformin in Recently Diagnosed Type 2 Diabetes.” Diabetes Care 25 (10): 1737–43.
Share
Print